Neurocrine Biosciences shows strong growth with rising INGREZZA sales, expanding pipeline, and solid financials despite key ...

The KINECT-PRO™ analysis is the first and only of its kind to report both remission of tardive dyskinesia symptoms and associated improvements in patient-reported outcomes. Post-hoc analysis from ...

CEO Kyle Gano highlighted Neurocrine's transformation into a fully integrated biopharmaceutical company. He emphasized the strong performance of INGREZZA, which is poised for double-digit ...

SAN DIEGO, Aug. 18, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration (FDA) has approved INGREZZA® (valbenazine) capsules for the ...

INGREZZA ® (valbenazine) Third Quarter Net Product Sales of $376 Million INGREZZA ® (valbenazine) 2022 Net Product Sales Guidance Raised to $1.4 - $1.425 Billion Supplemental New Drug Application ...

People with movement disorders can have a difficult time doing day-to-day activities, which could impact their independence. This can affect how people see themselves and affect their social life.

SAN DIEGO, Feb. 11, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the fourth quarter and fiscal year ended December 31, 2021 and provided ...